Ocrevus Zunovo: payments to doctors
Payments that named Ocrevus Zunovo as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $757K
- Providers
- 4,812
- Transactions
- 14,446
- Average per transaction
- $52
The per-transaction average — $52 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,812 providers the average total is $157, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $750,051 | 99.1% |
| Genentech, Inc. | $7,156 | 0.9% |